MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - GSK PHARMA
AUROBINDO PHARMA vs GSK PHARMA - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
GSK PHARMA 
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Current Valuations
| AUROBINDO PHARMA | GSK PHARMA | AUROBINDO PHARMA/ GSK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 10.7 | 52.9 | 20.2% | View Chart |
| P/BV | x | 2.3 | 11.1 | 20.9% | View Chart |
| Dividend Yield | % | 0.5 | 1.4 | 37.8% |
Financials
 AUROBINDO PHARMA  GSK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
GSK PHARMA Mar-19 |
AUROBINDO PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 3,595 | 22.5% | |
| Low | Rs | 504 | 1,253 | 40.2% | |
| Sales per share (Unadj.) | Rs | 281.1 | 184.7 | 152.2% | |
| Earnings per share (Unadj.) | Rs | 41.4 | 26.3 | 157.3% | |
| Cash flow per share (Unadj.) | Rs | 50.9 | 29.2 | 174.5% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 20.00 | 12.5% | |
| Dividend yield (eoy) | % | 0.4 | 0.8 | 46.2% | |
| Book value per share (Unadj.) | Rs | 199.4 | 126.3 | 157.8% | |
| Shares outstanding (eoy) | m | 585.88 | 169.40 | 345.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.3 | 13.1 | 17.8% | |
| Avg P/E ratio | x | 15.9 | 92.2 | 17.2% | |
| P/CF ratio (eoy) | x | 12.9 | 83.1 | 15.5% | |
| Price / Book Value ratio | x | 3.3 | 19.2 | 17.2% | |
| Dividend payout | % | 6.0 | 76.1 | 7.9% | |
| Avg Mkt Cap | Rs m | 384,630 | 410,626 | 93.7% | |
| No. of employees | `000 | 17.3 | 5.0 | 349.4% | |
| Total wages/salary | Rs m | 21,308 | 5,372 | 396.7% | |
| Avg. sales/employee | Rs Th | 9,500.7 | 6,306.7 | 150.6% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 1,083.1 | 113.5% | |
| Avg. net profit/employee | Rs Th | 1,397.9 | 898.0 | 155.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 31,281 | 526.4% | |
| Other income | Rs m | 1,020 | 1,023 | 99.7% | |
| Total revenues | Rs m | 165,686 | 32,304 | 512.9% | |
| Gross profit | Rs m | 37,718 | 6,009 | 627.7% | |
| Depreciation | Rs m | 5,580 | 486 | 1,148.1% | |
| Interest | Rs m | 777 | 6 | 12,953.3% | |
| Profit before tax | Rs m | 32,380 | 6,540 | 495.1% | |
| Minority Interest | Rs m | 31 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
| Tax | Rs m | 8,183 | 2,373 | 344.8% | |
| Profit after tax | Rs m | 24,229 | 4,454 | 544.0% | |
| Gross profit margin | % | 22.9 | 19.2 | 119.2% | |
| Effective tax rate | % | 25.3 | 36.3 | 69.6% | |
| Net profit margin | % | 14.7 | 14.2 | 103.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 20,061 | 607.5% | |
| Current liabilities | Rs m | 86,806 | 14,543 | 596.9% | |
| Net working cap to sales | % | 21.3 | 17.6 | 120.7% | |
| Current ratio | x | 1.4 | 1.4 | 101.8% | |
| Inventory Days | Days | 130 | 57 | 228.8% | |
| Debtors Days | Days | 68 | 14 | 486.2% | |
| Net fixed assets | Rs m | 81,037 | 14,343 | 565.0% | |
| Share capital | Rs m | 586 | 1,694 | 34.6% | |
| "Free" reserves | Rs m | 116,218 | 19,704 | 589.8% | |
| Net worth | Rs m | 116,804 | 21,398 | 545.9% | |
| Long term debt | Rs m | 4,512 | 2 | 225,600.0% | |
| Total assets | Rs m | 211,052 | 39,113 | 539.6% | |
| Interest coverage | x | 42.7 | 1,091.0 | 3.9% | |
| Debt to equity ratio | x | 0 | 0 | 41,329.5% | |
| Sales to assets ratio | x | 0.8 | 0.8 | 97.6% | |
| Return on assets | % | 11.8 | 11.4 | 103.9% | |
| Return on equity | % | 20.7 | 20.8 | 99.7% | |
| Return on capital | % | 27.4 | 31.9 | 85.7% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 80,727 | 534 | 15,117.5% | |
| Fx outflow | Rs m | 34,700 | 7,091 | 489.4% | |
| Net fx | Rs m | 46,027 | -6,557 | -702.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 3,994 | 489.5% | |
| From Investments | Rs m | -19,570 | -1,433 | 1,365.3% | |
| From Financial Activity | Rs m | 8,642 | -3,584 | -241.1% | |
| Net Cashflow | Rs m | 8,922 | -1,023 | -872.0% | |
Share Holding
| Indian Promoters | % | 54.1 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 50.7 | - | |
| Indian inst/Mut Fund | % | 8.0 | 10.2 | 77.9% | |
| FIIs | % | 27.7 | 23.8 | 116.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 15.4 | 66.2% | |
| Shareholders | 69,601 | 102,036 | 68.2% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: ORCHID PHARMA LTD CIPLA ASTRAZENECA PHARMA SUVEN LIFESCIENCES STERLING BIOTECH
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)
Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.
Related Views on News
AUROBINDO PHARMA Surges by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)
Oct 14, 2019 | Updated on Oct 14, 2019AUROBINDO PHARMA share price has surged by 6% and its current market price is Rs 464. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 5.7%). The top losers are FDC LTD. and DIVIS LABORATORIES (down 0.3%).
AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)
Jul 24, 2019 | Updated on Jul 24, 2019For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)
Oct 1, 2019How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?
Rebound Riches Could be Yours With These Stocks(Profit Hunter)
Oct 4, 2019The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.
The One Stock I Like in this Market(The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)
Oct 4, 2019Around Rs 75 billion poured into the Indian stock market in the month of September.
MoreAUROBINDO PHARMA SHARE PRICE
Oct 14, 2019 02:03 PM
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 8-QTR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.